ShockWave Medical, Inc. (SWAV)

NEW YORK , May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.

Charles Schwab Investment Management Inc. lifted its position in shares of Shockwave Medical, Inc. (NASDAQ:SWAV – Free Report) by 2.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 226,660 shares of the company’s stock after purchasing an additional 5,660 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.61% of Shockwave Medical worth $43,192,000 as of its most recent filing with the Securities & Exchange Commission. Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC bought a new position in shares of Shockwave Medical during the third quarter valued at approximately $82,000. Principal Financial Group Inc. increased its position in Shockwave Medical by 1.1% during the 3rd quarter. Principal Financial Group Inc. now owns 146,893 shares of the company’s stock valued at $29,246,000 after buying an additional 1,587 shares in the last quarter. EFG Asset Management North America Corp. raised its stake in Shockwave Medical by 2.1% during the third quarter. EFG Asset Management North America Corp. now owns 17,023 shares of the company’s stock valued at $3,390,000 after buying an additional 357 shares during the last quarter. Signaturefd LLC boosted its holdings in Shockwave Medical by 79.1% in the third quarter. Signaturefd LLC now owns 471 shares of the company’s stock worth $94,000 after acquiring an additional 208 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Shockwave Medical by 297.4% during the third quarter. EverSource Wealth Advisors LLC now owns 155 shares of the company’s stock valued at $31,000 after acquiring an additional 116 shares in the last quarter. 95.35% of the stock is owned by hedge funds and other institutional investors. Analyst Ratings Changes A number of analysts recently commented on SWAV shares. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $335.00 price objective (up previously from $270.00) on shares of Shockwave Medical in a research report on Monday, April 8th. SVB Leerink reissued a “market perform” rating and set a $335.00 price objective (down previously from $361.00) on shares of Shockwave Medical in a research report on Monday, April 8th. TheStreet raised Shockwave Medical from a “c+” rating to a “b” rating in a report on Thursday, February 15th. Leerink Partnrs downgraded Shockwave Medical from an “outperform” rating to a “market perform” rating in a research note on Friday, April 5th. Finally, Piper Sandler raised their target price on shares of Shockwave Medical from $290.00 to $360.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 2nd. Ten analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $309.11. Check Out Our Latest Stock Analysis on SWAV Insider Activity at Shockwave Medical In other Shockwave Medical news, Director Frederic H. Moll sold 60,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $257.39, for a total transaction of $15,443,400.00. Following the completion of the transaction, the director now owns 287,521 shares in the company, valued at $74,005,030.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Frank T. Watkins sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $253.65, for a total value of $507,300.00. Following the transaction, the director now owns 4,532 shares of the company’s stock, valued at approximately $1,149,541.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Frederic H. Moll sold 60,000 shares of Shockwave Medical stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $257.39, for a total transaction of $15,443,400.00. Following the sale, the director now owns 287,521 shares of the company’s stock, valued at approximately $74,005,030.19. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 72,120 shares of company stock worth $18,753,421. Insiders own 3.40% of the company’s stock. Shockwave Medical Price Performance SWAV stock opened at $330.13 on Monday. The company has a debt-to-equity ratio of 0.97, a quick ratio of 12.61 and a current ratio of 13.81. The company’s fifty day moving average price is $316.05 and its 200-day moving average price is $246.95. Shockwave Medical, Inc. has a one year low of $157.00 and a one year high of $331.58. The company has a market capitalization of $12.39 billion, a PE ratio of 77.13, a price-to-earnings-growth ratio of 2.41 and a beta of 0.88. Shockwave Medical (NASDAQ:SWAV – Get Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported $1.44 EPS for the quarter, topping the consensus estimate of $0.99 by $0.45. The business had revenue of $218.80 million for the quarter, compared to analysts’ expectations of $207.69 million. Shockwave Medical had a net margin of 20.75% and a return on equity of 24.79%. The business’s quarterly revenue was up 35.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.03 EPS. On average, equities analysts anticipate that Shockwave Medical, Inc. will post 5.03 EPS for the current fiscal year. Shockwave Medical Profile (Free Report) Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. Read More Five stocks we like better than Shockwave Medical 5 Top Rated Dividend Stocks to Consider MarketBeat Week in Review – 5/13 – 5/17 What is MarketRank? How to Use it Take-Two Interactive Software Offers 2nd Chance for Investors Stock Market Upgrades: What Are They? Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook Want to see what other hedge funds are holding SWAV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shockwave Medical, Inc. (NASDAQ:SWAV – Free Report).

Johnson & Johnson JNJ, +0.29% rolled out a four-part bond on Monday to help fund its planned $13 billion acquisition of Shockwave Medical, underscoring how the Federal Reserve's rate hikes haven't dulled the appetite on Wall Street for deal-making.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Shockwave Medical, Inc. (NasdaqGS: SWAV) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Shockwave will receive $335.00 in cash for each share of Shockwave that they own. KSF is seeking to determine whether this consideration and the process that led to it are.

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion amid JNJ entering into a definitive agreement to acquire the company.

Although the revenue and EPS for Shockwave Medical (SWAV) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Shockwave Medical (SWAV) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.03 per share a year ago.

SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024.

Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In the latest trading session, Shockwave Medical (SWAV) closed at $328.99, marking a +0.04% move from the previous day.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Shockwave Medical (SWAV) concluded the recent trading session at $329, signifying a +0.45% move from its prior day's close.

Shockwave Medical (SWAV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

We have narrowed our search to five high-flying Nasdaq Composite listed non-tech stocks with more upside left. These are: CELH, SWAV, COIN, HOOD, IBKR.

NEW YORK , April 9, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Shockwave Medical, Inc. (NASDAQ: SWAV)'s  sale to Johnson & Johnson for $335.00 per share in cash. If you are a Shockwave shareholder, click here to learn more about your rights and options.

NEW YORK , April 9, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Shockwave Medical, Inc. (Nasdaq: SWAV), relating to its proposed sale to Johnson & Johnson.